投资者： 贵司在脑机接口领域有没有布局，如有请介绍下 董秘： 尊敬的投资者，您好！公司始终关注尖端科技在医疗诊断环节的应用，未来会将这些新技术整 合进服务体系，为患者提供更高效、精准的诊断服务。谢谢！ 董秘最新回复 投资者： 董秘，你好！贵公司属于医疗数据行业的龙头吗？ 董秘： 尊敬的投资者，您好！公司是国内第三方医学诊断龙头企业，积累了海量的医疗数据，在医疗 数据应用方面处于领先地位。谢谢！ 投资者： 董秘，你好！请问贵公司有没有机器人相关的合作？ 董秘： 尊敬的投资者，您好！公司始终关注尖端科技在医疗诊断环节的应用，未来会将这些新技术整 合进服务体系，为患者提供更高效、精准的诊断服务。谢谢！ 投资者： 2024年公司回购近2亿元的股票，计划用于股权激励或预期注销，请问董秘：股权激励方案啥 时候发布？ 董秘： 尊敬的投资者，您好！有关股权激励情况请关注公司后续披露的公告。谢谢！ 截至2025年3月28日收盘，迪安诊断(300244)报收于15.88元，下跌1.12%，换手率3.04%，成交量15.24万 手，成交额2.44亿元。 当日关注点 交易信息汇总：当日主力资金净流入645.11万元，占总成交额2.6 ...

Summary of the Conference Call Company and Industry - **Company**: Di'an Diagnostics - **Industry**: AI in Medical Diagnostics Key Points and Arguments 1. **AI Medical Business Layout**: Di'an Diagnostics has been focusing on AI in the medical field, particularly in diagnostics and treatment, since 2021 with the establishment of a subsidiary, Yice Technology, specializing in AI pathology [1][2][3] 2. **Product Development**: The company has developed several AI products, including a cervical cancer diagnostic tool that received a Class II medical certification in 2023 and is expected to obtain a Class III certification by June 2023 [3][4] 3. **Market Penetration**: Di'an has signed contracts with approximately 70 local hospitals in Hubei Province, achieving over 50% market share in the digital pathology service system [3][4] 4. **AI Models**: The company has created a proprietary AI model called the Di'an Vertical Model, which is currently under review for official recognition [5][6] 5. **Collaboration with Hospitals**: Di'an collaborates with hospitals, such as Wuhan Union Hospital, to develop predictive models for chronic leukemia treatment, which have gained recognition both domestically and internationally [6][7] 6. **Health Management Initiatives**: Di'an has partnered with Huawei Cloud to enhance health management services, allowing users to upload health reports for risk assessments and personalized recommendations [7][8] 7. **Data Accumulation**: The company has accumulated 5.4 PB of valuable data from approximately 160 million tests conducted annually, with a growth rate of about 100 TB per month [16][17] 8. **Clinical Research Database**: Di'an has launched a clinical research database in collaboration with major hospitals, integrating clinical data with multi-omics data for research purposes [17][18] 9. **Regulatory Compliance**: The company has obtained various certifications for data security and compliance, enhancing its credibility in the data management sector [18][19] 10. **Future Business Opportunities**: Di'an plans to commercialize its AI tools through various channels, including diagnostic testing packages, clinical decision support tools, and smart laboratory products [14][15][20] Additional Important Content 1. **Competitive Landscape**: Di'an acknowledges competition in the AI pathology space, particularly from partnerships like that of Huawei and Ruijin Hospital, but emphasizes its unique data advantages and focus on clinical applications [22][23] 2. **Differentiation in AI Models**: Di'an's AI models are tailored for specific diseases, leveraging extensive data for productization, which sets them apart from competitors focusing on broader applications [24][25] 3. **Market Trends**: The company is observing interest from other provinces in replicating Hubei's digital pathology model, indicating potential for expansion [25][26] 4. **Data Annotation Team**: The company is expanding its data annotation team to manage the increasing volume of data, which is crucial for training AI models [35]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 迪安诊断技术集团股份有限公司（以下简称"公司"或"迪安诊断"）股票连 续三个交易日内（2025年2月13日、2月14日、2月17日）收盘价格涨幅偏离值累计达 到30%以上，根据《深圳证券交易所交易规则》的有关规定，属于股票交易异常波动 情形。 证券代码：300244 证券简称：迪安诊断 公告编号：2025-003 迪安诊断技术集团股份有限公司 关于股票交易异常波动的公告 公司董事会确认，公司目前没有任何根据《深圳证券交易所创业板股票上市规 则》等有关规定应予以披露而未披露的事项或与该事项有关的筹划、商谈、意向、 协议等；董事会也未获悉本公司有根据《深圳证券交易所创业板股票上市规则》等 有关规定应予以披露而未披露的、对本公司股票及其衍生品种交易价格产生较大影 响的信息；公司前期披露的信息不存在需要更正、补充之处。 四、风险提示 1. 经自查，公司不存在违反信息公平披露的情形。 二、公司关注并核实相关情况 针对公司股票异常波动情况，公司董事会通过电话、现场等问询方式，对相关 问题进行了 ...

Summary of Conference Call Company and Industry Involved - The conference call primarily discusses the advancements and strategies of a company involved in medical diagnostics, particularly focusing on AI applications in pathology and health management. Key Points and Arguments AI in Diagnostics and Treatment - The company is leveraging AI technology in pathology to enhance drug development processes, particularly in clinical testing and analysis [1] - Collaborations with leading hospitals, such as Huazhong University of Science and Technology, are aimed at developing predictive models for chronic diseases like chronic leukemia [2] - The company has established a Chronic Leukemia Discontinuation Alliance to promote predictive models in treatment [3] - A strategic partnership with Huawei focuses on AI health management, utilizing health data to generate risk assessments for major diseases [4] Health Management Applications - The AI health management system aims to provide personalized health promotion and risk assessments based on individual health data [5] - The company is developing a comprehensive AI-driven health management tool that can be utilized by both patients and healthcare providers [11] Data and AI Model Development - The company has built a robust data platform that integrates extensive medical testing data for AI training and model development [8] - A new AI model named "启迪索威" is being developed, focusing on multi-modal applications in medical diagnostics [10] - The company emphasizes the importance of data quality and governance in AI model training, having processed approximately 60 million valuable samples for research and AI learning [14] Market Strategy and Commercialization - The company has signed agreements with over 70 hospitals in Hubei for AI pathology services, achieving a market share of approximately 70% in that region [29] - The pricing strategy for AI pathology services is competitive, with costs ranging from 60 to 300 RMB per test, reflecting the value of AI in enhancing diagnostic accuracy [44] - The company aims to expand its market presence by promoting AI solutions in collaboration with government initiatives and healthcare institutions [19][20] Future Outlook - The company is optimistic about the growth of AI applications in healthcare, particularly in diagnostics and health management, as the technology becomes more accessible [40] - There is a focus on developing digital products as part of a five-year strategic plan, with an emphasis on integrating AI into existing healthcare solutions [41] Challenges and Industry Dynamics - The medical diagnostics industry is experiencing significant changes, with a notable number of companies exiting the market, leading to increased competition and consolidation [49] - The company is prepared to adapt to regulatory changes and market demands, ensuring compliance and maintaining a competitive edge [48] Other Important but Overlooked Content - The company has a dedicated AI research team, including experts from various fields, to enhance its technological capabilities [6] - There is a strong emphasis on collaboration with external experts and institutions to drive innovation in AI applications [7] - The company is also exploring the potential for data monetization through compliance with legal and regulatory standards [16][17] This summary encapsulates the key discussions and insights from the conference call, highlighting the company's strategic initiatives, market positioning, and future outlook in the medical diagnostics industry.

Investment Rating - The report assigns a "Buy" rating to the company, indicating a potential upside of 15% to 35% [5][10]. Core Insights - The company is expected to report a net loss of RMB 270 million to 370 million in 2024, primarily due to significant impairment losses on receivables and goodwill [8]. - The company is building an AI ecosystem for diagnostic and treatment services, leveraging its own computing power and cloud resources [8]. - The forecasted net profits for 2024, 2025, and 2026 are RMB -340 million, RMB 650 million, and RMB 720 million, respectively, with an expected EPS of RMB -0.55, RMB 1.03, and RMB 1.15 [8]. Financial Summary - The company's revenue is projected to decline from RMB 12,172 million in 2023 to RMB 12,741 million in 2025, before increasing to RMB 13,317 million in 2026 [13]. - The net profit for 2023 is expected to be RMB 307 million, with a significant drop to RMB -344 million in 2024, followed by a recovery in subsequent years [7][13]. - The company's total assets are expected to decrease from RMB 17,939 million in 2023 to RMB 16,485 million in 2024, before gradually increasing to RMB 19,466 million by 2026 [13].

Summary of the Conference Call Company and Industry Overview - The conference call focused on **Dian Diagnostics**, a comprehensive medical diagnostic service provider, discussing its advancements in **AI** and future commercialization prospects in the healthcare industry [1][2]. Key Points and Arguments AI Development and Applications - Dian has established a specialized AI company, **Yicai Technology**, focusing on pathology, leveraging over **100,000 pathology samples** for AI applications [2][3]. - In **2023**, Dian obtained a Class II medical device certification for its digital products and is in the process of acquiring a Class III certification, expected by **June 2025** [3]. - The company has partnered with **70+ local hospitals** in Hubei to create a digital pathology service system, achieving a **70%** implementation rate in the region [3]. - Over **3 million AI pathology diagnostic reports** have been provided to various hospitals and clients [3]. Treatment Innovations - A strategic collaboration with **Wuhan Tongji Medical College** focuses on developing a predictive model for chronic myeloid leukemia (CML) treatment, which has been presented at the **American Society of Hematology** [4][5]. - The predictive model aims to determine whether patients can reduce or stop medication, enhancing treatment efficiency and reducing costs [5][36]. Health Management and Personalized Medicine - Dian is integrating AI into personalized healthcare management, utilizing health data from wearable devices and health reports to generate health promotion documents and risk assessments [6][7]. - The company is developing precision diagnosis centers in collaboration with hospitals to enhance personalized medical services [6]. AI Ecosystem and Team Development - Dian has built a robust AI ecosystem, including a team led by **Dr. Wang Yu**, previously from Alibaba's DAMO Academy, focusing on medical imaging AI [8][9]. - The AI infrastructure includes partnerships with **Huawei** and **Alibaba Cloud** for computational resources, and a proprietary big data platform with nearly **60 million samples** for disease and discipline tagging [10][15]. Data Security and Compliance - Dian has received certifications for data security management, including **ISO 27001** and **DSM**, ensuring compliance with data protection regulations [17][18]. - The company emphasizes the importance of data quality and quantity in AI model development, with a focus on maintaining patient privacy and data security [49]. Commercialization Strategies - Dian's AI business model includes various revenue streams, such as AI-enhanced diagnostic products, health management tools, and data services for healthcare institutions [31][34]. - The company is exploring partnerships with external software providers to integrate AI tools into healthcare practices [32]. Future Outlook - The management expressed optimism about the future growth of AI applications in healthcare, emphasizing the potential for AI to enhance existing services and create new business opportunities [40][54]. - The focus remains on leveraging Dian's unique data resources and industry expertise to drive innovation and improve patient outcomes [53][54]. Other Important but Overlooked Content - The call highlighted the challenges of AI implementation in healthcare, including the need for significant computational resources and the fragmentation of medical data across various institutions [51][52]. - There is a recognition of increasing competition in the AI healthcare space, prompting Dian to focus on its unique strengths and customer base [53]. This summary encapsulates the key discussions and insights from the conference call, providing a comprehensive overview of Dian Diagnostics' current position and future strategies in the AI healthcare landscape.

Financial Performance - The estimated net profit attributable to shareholders for 2024 is expected to be a loss of between 27 million and 37 million yuan, compared to a profit of 30.75 million yuan in the previous year[3]. - The estimated net profit after deducting non-recurring gains and losses is expected to be a loss of between 30 million and 40 million yuan, compared to a profit of 29.48 million yuan in the previous year[3]. - Non-recurring gains and losses are expected to impact the net profit attributable to shareholders by an amount between 20 million and 50 million yuan, mainly from government subsidies and asset disposal gains[6]. Client and Revenue Insights - The company reported a significant increase in the number of new clients, with an operating cash flow of approximately 1.2 billion yuan during the reporting period[5]. - The overall operating revenue is under pressure due to slowing market demand and intensified industry competition[5]. Impairment Provisions - The annual provision for credit impairment losses is estimated to be between 450 million and 500 million yuan due to extended collection periods for some accounts receivable[6]. - The company anticipates goodwill impairment provisions of between 350 million and 420 million yuan due to underperformance of certain subsidiaries[6]. Strategic Focus - The company is focusing on enhancing supply chain efficiency, maximizing human resource effectiveness, and digital transformation to support sustainable development[5]. - The company is increasing R&D investment in key disease testing projects and expanding into emerging markets such as Guangdong and Vietnam[6]. Accounting Communication - The company has communicated with its accounting firm regarding the financial data related to the earnings forecast, and there are no discrepancies[4].

证券代码：300244 证券简称：迪安诊断 公告编号：2024-086 1. 陈海斌先生及其一致行动人杭州迪安控股有限公司未来半年和一年分别 到期的股票质押情况： 迪安诊断技术集团股份有限公司 关于控股股东部分股份解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 迪安诊断技术集团股份有限公司（以下简称"公司"）于近日接到公司控股 股东陈海斌先生通知，获悉其将持有的公司部分股份办理了解除质押，相关解除 质押手续已办理完毕。具体事项如下： 二、股东所持股份累计被质押的情况 截至公告披露日，控股股东陈海斌先生及其一致行动人杭州迪安控股有限 股东名称 是否为控股股东 或第一大股东及 其一致行动人 本次解除质 押股份数量 （万股） 占其所持 股份比例 占公司 总股本 比例 质押起始日 质押解除日 质权人 陈海斌 是 326 1.98% 0.52% 2022/7/25 2024/12/25 招商证券股 份有限公司 陈海斌 是 174 1.06% 0.28% 2023/6/20 2024/12/25 招商证券股 份有限公司 合计 - 500 3.04% 0.8 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for future performance [5]. Core Views - The company has faced significant pressure on its performance in the first three quarters of 2024, with a revenue decline of 10.05% year-on-year and a net profit drop of 75.35% [2][5]. - Despite the challenges, the company is expanding its precision centers and accelerating international exploration, which may provide a second growth curve [5][4]. - The improvement in operating cash flow is notable, with a shift from negative to positive cash flow in the reporting period [3]. Summary by Sections Financial Performance - In the first three quarters of 2024, the company reported revenue of 9.258 billion yuan, a decrease of 10.05% year-on-year, and a net profit of 131 million yuan, down 75.35% [2]. - The gross margin for the first three quarters was 28.05%, a decline of 4.76 percentage points compared to the previous year, while the net margin was 3.27%, down 4.42 percentage points [3]. Cost Management - The sales expense ratio increased to 9.47%, up 0.85 percentage points year-on-year, while the management expense ratio decreased to 5.91%, down 0.41 percentage points [3]. - The company has focused on improving cash flow management, resulting in operating cash flow of 54 million yuan at the end of the reporting period [3]. Strategic Initiatives - The company has added 4 new precision centers in Q3 2024, bringing the total to 84, with 52 centers already profitable [4]. - The international expansion includes the opening of a laboratory in Vietnam, which is expected to contribute to overseas growth [4]. Future Projections - Revenue projections for 2024-2026 are estimated at 12.683 billion yuan, 13.717 billion yuan, and 14.735 billion yuan, respectively [5]. - The adjusted net profit forecasts for the same period are 261 million yuan, 501 million yuan, and 682 million yuan, reflecting a downward revision due to declining gross margins [5].

证券代码：300244 证券简称：迪安诊断 公告编号：2024-085 迪安诊断技术集团股份有限公司 关于控股股东部分股份解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 迪安诊断技术集团股份有限公司（以下简称"公司"）于近日接到公司控股 股东陈海斌先生通知，获悉其将持有的公司部分股份办理了解除质押，相关解除 质押手续已办理完毕。具体事项如下： 二、股东所持股份累计被质押的情况 截至公告披露日，控股股东陈海斌先生及其一致行动人杭州迪安控股有限 | 公司所持质押股份情况如下： | | --- | 1. 陈海斌先生及其一致行动人杭州迪安控股有限公司未来半年和一年分别 | | | | | | | 已质押股份情况 | | 未质押股份 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 本次解除 | 本次解除 | | | | | 情况 | | | 股东 | 持股数量 | 持股 质押前质 | 质押后质 | 占其所 | 占公司 | | | 未质押 | | | | | | ...